Publications
- Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study2021 | First Faculty of Medicine
- Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors2020 | First Faculty of Medicine
- Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study2016 | First Faculty of Medicine
- ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas2016 | First Faculty of Medicine
- The retrospective review of the patients with NETs treated in General Hospital on PraguePublication without faculty affiliation
- Combined oral metronomic and biodifferentiating anti-angiogenic therapy with gastroentero-pancreatic patients with neuroendocrine tumors (GEP-NETs)Publication without faculty affiliation
- Relative risk analysis of safety profile of lanreotide autogel/depot vs. placebo in patients with pancreatic and intestinal neuroendocrine tumoursPublication without faculty affiliation
- The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms2022 | First Faculty of Medicine
- Expression of molecules of the Wnt pathway and of E-cadherin in the etiopathogenesis of human thymomas2020 | First Faculty of Medicine, Second Faculty of Medicine
- Peptid-receptor radionuklidová terapie v České republice2020 | First Faculty of Medicine, Second Faculty of Medicine
Loading network view...